Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413811 | 1.00 | CYP2D6 (0.40) | CYP2D6CUL4AGRM1CYP1A2CYP3A4 | |
| SCHEMBL3848931 | 0.92 | CHEK1 (0.36) | CYP2D6CUL4AGRM1CYP1A2CYP3A4 | |
| SCHEMBL8610235 | 0.84 | DRD2 (0.44) | CYP2D6CYP1A2CYP3A4MAPTLMNA | |
| SCHEMBL292551 | 0.80 | GRM1 (0.32) | CYP2D6CUL4AGRM1GRM5HTR2C | |
| SCHEMBL7918631 | 0.79 | CYP1A2 (0.48) | CYP2D6CYP1A2CYP3A4MAPTLMNA | |
| SCHEMBL24704510 | 0.78 | EPHX1 (0.37) | CYP2D6GRM1SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL11629050 | 0.78 | CYP2A6 (0.44) | MAPTMAPK1MEN1KMT2AGAA | |
| SCHEMBL20979795 | 0.78 | GRM1 (0.33) | CYP2D6GRM1LMNATP53HTR2C | |
| SCHEMBL29562474 | 0.78 | HTR7 (0.45) | CYP2D6CYP1A2CYP3A4MAPTLMNA | |
| SCHEMBL2030957 | 0.78 | MAPT (0.50) | MAPTLMNATP53MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042910-B1 | 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C | GILEAD PHARMASSET LLC (US) | 2019-01-09 | — | — | EP | claimed |
| US-8680262-B2 | Purification of oligonucleotides | GIRINDUS AG (DE) | 2014-03-25 | — | — | US | claimed |
| US-20130066061-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2013-03-14 | — | — | US | claimed |
| US-20100087635-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2010-04-08 | — | — | US | claimed |
| EP-1846431-A1 | PURIFICATION OF OLIGONUCLEOTIDES | Girindus AG (DE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006079660-A1 | PURIFICATION OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2006-08-03 | — | — | WO | claimed |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-21 | — | — | US | disclosed |
| US-11957703-B2 | Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs and derivatives of same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-09-21 | — | — | US | disclosed |
| EP-1386925-A1 | Method for preparing oligonucleotides | Girindus AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957703-B2 | Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs and derivatives of same | NAMPT, NUDT15, NME4 | CYP2D6 4840/4885CUL4A 1655/4885GRM1 4401/4885 |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | CYP2D6 1175/4885CUL4A 4535/4885GRM1 4677/4885 |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NUDT15, NME4 | CYP2D6 4840/4885CUL4A 1655/4885GRM1 4401/4885 |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | CYP2D6 3377/4885CUL4A 3899/4885GRM1 4328/4885 |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | RNGTT, NSUN2, POLN | CYP2D6 4458/4885CUL4A 3614/4885GRM1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.